These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 19362675

  • 21. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
    Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, MOVER Study Group.
    Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
    [Abstract] [Full Text] [Related]

  • 22. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES.
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Fracture risk and zoledronic acid therapy in men with osteoporosis.
    Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E.
    N Engl J Med; 2012 Nov 01; 367(18):1714-23. PubMed ID: 23113482
    [Abstract] [Full Text] [Related]

  • 25. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
    McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR.
    Osteoporos Int; 2013 Jan 01; 24(1):301-10. PubMed ID: 23079690
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial.
    Fujieda Y, Horita T, Nishimoto N, Tanimura K, Amasaki Y, Kasahara H, Furukawa S, Takeda T, Fukaya S, Matsui K, Tsutsumi A, Furusaki A, Sagawa A, Katayama K, Takeuchi K, Katsumata K, Kurita T, Shane P, Kato M, Oku K, Yasuda S, Takahata M, Iwasaki N, Atsumi T.
    Mod Rheumatol; 2021 May 01; 31(3):593-599. PubMed ID: 32820698
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
    Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW.
    Ann Intern Med; 2006 Feb 21; 144(4):239-48. PubMed ID: 16490909
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
    Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG.
    Osteoporos Int; 2000 Feb 21; 11(4):331-7. PubMed ID: 10928223
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 34. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A.
    Clin Ther; 2010 Mar 03; 32(3):426-36. PubMed ID: 20399982
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD.
    Drug Saf; 2006 Mar 03; 29(12):1133-52. PubMed ID: 17147460
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM.
    Nat Clin Pract Rheumatol; 2006 Apr 03; 2(4):186-7. PubMed ID: 16932682
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.